Adma Biologics, Inc. ADMA Prévisions boursières
Prédiction de prix et analyse propulsées par l'IA pour Adma Biologics, Inc. · Mise à jour Mar 30, 2026
Prévision IA à 90 jours
ACHAT FORT
7 jours
30 jours
90 jours
Confiance de l'IA: -3% Corrélation de Spearman
mars 30, 2026
Voir l'objectif de prix exact de ADMA
Créez un compte gratuit pour débloquer les prédictions IA pour plus de 4 000 actions
Inscrivez-vous gratuitement avec Google✓ Compte gratuit · ✓ Essai de 30 jours · ✓ Annuler à tout moment
Graphique des prix
Chargement du graphique...
Statistiques clés
Capitalisation boursière
$2.18B
Ratio P/E
14,8x
Ratio P/B
4,56x
BPA
$0,89
ROE
-65,4%
Marge nette
129,8%
Chiffre d'affaires
$510M
Ratio de liquidité générale
7,60x
Ratio D/CP
1,15x
A propos de Adma Biologics, Inc.
Adma Biologics, Inc. (ADMA) opère dans le secteur Life Sciences, spécifiquement dans le secteur Biological Products, (No Diagnostic Substances). L'entreprise emploie environ 302 personnes.
We do not have any company description for ADMA BIOLOGICS, INC. at the moment.
Dernières actualités
- ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman ...
- ADMA Biologics Addresses Misleading Short-Seller Report
- ADMA Biologics slams short seller claims, highlights strong demand
- Inscrivez-vous gratuitement pour lire les 10 articles →
Biological Products, (No Diagnostic Substances) Entreprises comparables
| Entreprise | Ticker | Signal IA | Capitalisation boursière | P/E |
|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. | ABOS | ██% | $170M | -1,9x |
| Abpro Holdings, Inc. | ABP | ██% | $310K | -x |
| Arcellx, Inc. | ACLX | ██% | $6.65B | -74,1x |
| Alpha Cognition Inc. | ACOG | ██% | $116M | -x |
| Adaptimmune Therapeutics Plc | ADAP | ██% | $77M | -13,2x |
| Adma Biologics, Inc. | ADMA | ██% | $2.18B | 14,8x |
| Adaptive Biotechnologies Corp | ADPT | ██% | $1.98B | -4,6x |
| Adverum Biotechnologies, Inc. | ADVM | ██% | $95M | -1,8x |
| Agenus Inc | AGEN | ██% | $114M | 995,1x |
| Agentix Corp. | AGTX | ██% | $2M | -x |
| Aim Immunotech Inc. | AIM | ██% | $2M | -0,5x |
| Aim Immunotech Inc. | AIMI | ██% | $1M | -x |
| Alector, Inc. | ALEC | ██% | $223M | -1,2x |
| Aligos Therapeutics, Inc. | ALGS | ██% | $41M | -19,2x |
| Allogene Therapeutics, Inc. | ALLO | ██% | $509M | -1,4x |
| Alvotech | ALVO | ██% | $1.07B | -x |
| Amgen Inc | AMGN | ██% | $189.58B | 24,6x |
| Apogee Therapeutics, Inc. | APGE | ██% | $5.38B | -20,5x |
| Aptose Biosciences Inc. | APTOF | ██% | $4M | -x |
| Argenx Se | ARGX | ██% | $41.93B | -x |
| Armata Pharmaceuticals, Inc. | ARMP | ██% | $315M | -1,0x |
| Artiva Biotherapeutics, Inc. | ARTV | ██% | $133M | -x |
| Leonabio, Inc. | ATHA | ██% | $23M | -0,2x |
| Atara Biotherapeutics, Inc. | ATRA | ██% | $35M | 1,1x |
| Atyr Pharma Inc | ATYR | ██% | $76M | -3,6x |
| Aura Biosciences, Inc. | AURA | ██% | $425M | -4,9x |
| Autolus Therapeutics Plc | AUTL | ██% | $386M | -x |
| Anavex Life Sciences … | AVXL | ██% | $261M | -17,3x |
| Bioatla, Inc. | BCAB | ██% | $13M | -1,1x |
| Biocardia, Inc. | BCDA | ██% | $12M | -0,6x |
| Brainstorm Cell Therapeutics … | BCLI | ██% | $8M | -4,9x |
| Biocryst Pharmaceuticals Inc | BCRX | ██% | $2.37B | 9,0x |
| Black Diamond Therapeutics, … | BDTX | ██% | $116M | 5,2x |
| Beam Therapeutics Inc. | BEAM | ██% | $2.23B | -12,6x |
| Biogen Inc. | BIIB | ██% | $27.54B | 21,3x |
| Biontech Se | BNTX | ██% | $21.43B | -x |
| Cabaletta Bio, Inc. | CABA | ██% | $286M | -1,6x |
| Candel Therapeutics, Inc. | CADL | ██% | $328M | -4,6x |
| C4 Therapeutics, Inc. | CCCC | ██% | $228M | -2,6x |
| Cidara Therapeutics, Inc. | CDTX | ██% | $6.49B | -1,0x |
| Creative Medical Technology … | CELZ | ██% | $7M | -3,4x |
| Cero Therapeutics Holdings, … | CERO | ██% | $720K | -x |
| Cullinan Therapeutics, Inc. | CGEM | ██% | $847M | -4,1x |
| Compugen Ltd | CGEN | ██% | $188M | -x |
| Cg Oncology, Inc. | CGON | ██% | $5.16B | -x |
| Cognition Therapeutics Inc | CGTX | ██% | $68M | -0,5x |
| Coherus Oncology, Inc. | CHRS | ██% | $265M | 1,6x |
| Calidi Biotherapeutics, Inc. | CLDI | ██% | $2M | -0,9x |
| Cellectis S.A. | CLLS | ██% | $319M | -x |
| Compass Therapeutics, Inc. | CMPX | ██% | $909M | -4,8x |
| Mosaic Immunoengineering Inc. | CPMV | ██% | $5M | -x |
| Caribou Biosciences, Inc. | CRBU | ██% | $142M | -1,5x |
| Cardiff Oncology, Inc. | CRDF | ██% | $106M | -4,0x |
| Cardiol Therapeutics Inc. | CRDL | ██% | $136M | -x |
| Curis Inc | CRIS | ██% | $20M | -0,3x |
| Crispr Therapeutics Ag | CRSP | ██% | $4.25B | -12,1x |
| Champions Oncology, Inc. | CSBR | ██% | $80M | 32,9x |
| Cel Sci Corp | CVM | ██% | $26M | -0,9x |
| Dbv Technologies S.A. | DBVT | ██% | $1.13B | -3,3x |
| Dbv Technologies S.A. | DBVTF | ██% | $10K | -x |
| Ginkgo Bioworks Holdings, … | DNA | ██% | $319M | -13,9x |
| Denali Therapeutics Inc. | DNLI | ██% | $2.82B | -8,7x |
| Precision Biosciences Inc | DTIL | ██% | $131M | -2,2x |
| Dyadic International Inc | DYAI | ██% | $31M | -7,3x |
| Editas Medicine, Inc. | EDIT | ██% | $218M | -0,8x |
| Elutia Inc. | ELUT | ██% | $44M | 0,8x |
| Engene Holdings Inc. | ENGN | ██% | $414M | 3,7x |
| Entera Bio Ltd. | ENTX | ██% | $51M | 8,5x |
| Viskase Holdings, Inc. | ENZN | ██% | $4M | -x |
| Estrella Immunopharma, Inc. | ESLA | ██% | $42M | -3,1x |
| Evaxion A/S | EVAX | ██% | $31M | -x |
| Exelixis, Inc. | EXEL | ██% | $11.01B | 14,1x |
| Exozymes Inc. | EXOZ | ██% | $61M | -x |
| Fate Therapeutics Inc | FATE | ██% | $122M | -1,3x |
| 4d Molecular Therapeutics, … | FDMT | ██% | $438M | -3,0x |
| Fennec Pharmaceuticals Inc. | FENC | ██% | $210M | 1758,3x |
| Finch Therapeutics Group, … | FNCH | ██% | $15M | -0,1x |
| Futuretech Ii Acquisition … | FTII | ██% | $52M | -x |
| Futuretech Ii Acquisition … | FTIIU | ██% | $14M | -x |
| Gilead Sciences, Inc. | GILD | ██% | $169.20B | 19,9x |
| Monte Rosa Therapeutics, … | GLUE | ██% | $1.32B | 59,5x |
| Genenta Science S.P.A. | GNTA | ██% | $16M | -x |
| Green Planet Bio … | GPLB | ██% | $340K | -x |
| Halozyme Therapeutics, Inc. | HALO | ██% | $7.32B | 23,1x |
| Humacyte, Inc. | HUMA | ██% | $128M | -3,3x |
| Immunitybio, Inc. | IBRX | ██% | $6.74B | -3,6x |
| Inhibikase Therapeutics, Inc. | IKT | ██% | $194M | -1,0x |
| Immunocore Holdings Plc | IMCR | ██% | $1.48B | -x |
| Immatics N.V. | IMTX | ██% | $1.25B | -x |
| Immunovant, Inc. | IMVT | ██% | $4.85B | -14,5x |
| In8bio, Inc. | INAB | ██% | $13M | -x |
| Inhibrx Biosciences, Inc. | INBX | ██% | $873M | -6,8x |
| Mink Therapeutics, Inc. | INKT | ██% | $45M | -1,5x |
| Inmune Bio, Inc. | INMB | ██% | $30M | -2,5x |
| Intensity Therapeutics, Inc. | INTS | ██% | $14M | -2,2x |
| Iovance Biotherapeutics, Inc. | IOVA | ██% | $1.45B | -4,5x |
| Century Therapeutics, Inc. | IPSC | ██% | $365M | -0,7x |
| Invivyd, Inc. | IVVD | ██% | $367M | -0,4x |
| Jasper Therapeutics, Inc. | JSPR | ██% | $25M | -3,2x |
| Kalaris Therapeutics, Inc. | KLRS | ██% | $121M | -x |
| Klotho Neurosciences, Inc. | KLTO | ██% | $56M | -x |
| Kodiak Sciences Inc. | KOD | ██% | $2.35B | -2,5x |
| Krystal Biotech, Inc. | KRYS | ██% | $7.21B | 35,2x |
| Kymera Therapeutics, Inc. | KYMR | ██% | $6.46B | -17,8x |
| Kyverna Therapeutics, Inc. | KYTX | ██% | $458M | -x |
| Ladrx Corp | LADX | ██% | $20K | -x |
| Lineage Cell Therapeutics, … | LCTX | ██% | $360M | -4,7x |
| Lenz Therapeutics, Inc. | LENZ | ██% | $357M | -6,7x |
| Liminatus Pharma, Inc. | LIMN | ██% | $10M | -x |
| Lexeo Therapeutics, Inc. | LXEO | ██% | $385M | -0,4x |
| Maze Therapeutics, Inc. | MAZE | ██% | $1.43B | -x |
| Mesoblast Ltd | MESO | ██% | $1.90B | -x |
| Meiragtx Holdings Plc | MGTX | ██% | $596M | -3,4x |
| Metagenomi Therapeutics, Inc. | MGX | ██% | $50M | -x |
| Molecular Partners Ag | MOLN | ██% | $160M | -x |
| Moderna, Inc. | MRNA | ██% | $20.02B | -3,2x |
| Neurocrine Biosciences Inc | NBIX | ██% | $12.80B | 26,7x |
| Nkgen Biotech, Inc. | NKGN | ██% | $2M | -0,1x |
| Neumora Therapeutics, Inc. | NMRA | ██% | $399M | -3,9x |
| Novavax Inc | NVAX | ██% | $1.51B | 3,4x |
| Ocugen, Inc. | OCGN | ██% | $547M | -4,3x |
| Outlook Therapeutics, Inc. | OTLK | ██% | $22M | -0,2x |
| Palisade Bio, Inc. | PALI | ██% | $291M | -0,2x |
| Passage Bio, Inc. | PASG | ██% | $22M | -0,6x |
| Vaxcyte, Inc. | PCVX | ██% | $7.62B | -20,4x |
| Biomx Inc. | PHGE | ██% | $8M | 1,5x |
| Pluri Inc. | PLUR | ██% | $34M | -1,4x |
| Protalix Biotherapeutics, Inc. | PLX | ██% | $173M | 41,2x |
| Pharmacyte Biotech, Inc. | PMCB | ██% | $8M | 0,3x |
| Prime Medicine, Inc. | PRME | ██% | $617M | -1,5x |
| Prokidney Corp. | PROK | ██% | $526M | -x |
| Qiagen N.V. | QGEN | ██% | $9.11B | -x |
| Quince Therapeutics, Inc. | QNCX | ██% | $5M | -1,7x |
| Qrons Inc. | QRON | ██% | $150K | -x |
| Replimune Group, Inc. | REPL | ██% | $602M | -3,8x |
| Repligen Corp | RGEN | ██% | $6.61B | 135,2x |
| Regenxbio Inc. | RGNX | ██% | $418M | -1,8x |
| Relay Therapeutics, Inc. | RLAY | ██% | $1.84B | -2,0x |
| Revolution Medicines, Inc. | RVMD | ██% | $19.08B | -11,1x |
| Recursion Pharmaceuticals, Inc. | RXRX | ██% | $1.58B | -4,7x |
| Sab Biotherapeutics, Inc. | SABS | ██% | $273M | 20,6x |
| Sana Biotechnology, Inc. | SANA | ██% | $740M | -2,1x |
| Scilex Holding Co | SCLX | ██% | $47M | -0,4x |
| Scinai Immunotherapeutics Ltd. | SCNI | ██% | $2M | -287,8x |
| Sangamo Therapeutics, Inc | SGMO | ██% | $82M | -1,6x |
| Solid Biosciences Inc. | SLDB | ██% | $715M | -0,9x |
| Silexion Therapeutics Corp | SLXN | ██% | $4M | -x |
| Senti Biosciences, Inc. | SNTI | ██% | $24M | -1,1x |
| Scholar Rock Holding … | SRRK | ██% | $5.22B | -18,5x |
| Surrozen, Inc./De | SRZN | ██% | $343M | -0,5x |
| Sutro Biopharma, Inc. | STRO | ██% | $356M | -1,0x |
| Protara Therapeutics, Inc. | TARA | ██% | $278M | -2,1x |
| Tarsus Pharmaceuticals, Inc. | TARS | ██% | $2.87B | -12,4x |
| Tc Biopharm (Holdings) … | TCBPY | ██% | $10K | -x |
| Tscan Therapeutics, Inc. | TCRX | ██% | $57M | -4,6x |
| Bio-Techne Corp | TECH | ██% | $8.20B | 101,1x |
| Tectonic Therapeutic, Inc. | TECX | ██% | $587M | -8,9x |
| Instil Bio, Inc. | TIL | ██% | $56M | -1,1x |
| Tenaya Therapeutics, Inc. | TNYA | ██% | $159M | -2,5x |
| Tourmaline Bio, Inc. | TRML | ██% | $1.23B | -3,5x |
| Taysha Gene Therapies, … | TSHA | ██% | $1.26B | -3,0x |
| Titan Pharmaceuticals Inc | TTNP | ██% | $6M | -0,5x |
| Tevogen Bio Holdings … | TVGN | ██% | $17M | -x |
| Twist Bioscience Corp | TWST | ██% | $2.85B | -12,6x |
| Voyager Acquisition Corp./Cayman … | VACH | ██% | $372M | 41,3x |
| Voyager Acquisition Corp./Cayman … | VACHU | ██% | $68M | 6,7x |
| Valneva Se | VALN | ██% | $548M | -x |
| Vericel Corp | VCEL | ██% | $1.61B | 97,7x |
| Vir Biotechnology, Inc. | VIR | ██% | $1.47B | -2,0x |
| Vivosim Labs, Inc. | VIVS | ██% | $4M | -x |
| Vor Biopharma Inc. | VOR | ██% | $738M | -0,6x |
| Vaxart, Inc. | VXRT | ██% | $146M | 8,9x |
| Voyager Therapeutics, Inc. | VYGR | ██% | $238M | 570,6x |
| Windtree Therapeutics Inc … | WINT | ██% | $320K | -0,4x |
| X4 Pharmaceuticals, Inc | XFOR | ██% | $375M | 6,4x |
| Zeo Scientifix, Inc. | ZEOX | ██% | $17M | -x |
| Zivo Bioscience, Inc. | ZIVO | ██% | $26M | -31,3x |
| Zura Bio Ltd | ZURA | ██% | $565M | -x |
FAQ
-
Adma Biologics, Inc. est-il une bonne action à acheter ?
Notre IA analyse Adma Biologics, Inc. quotidiennement. Consultez le signal ci-dessus pour la dernière recommandation. Effectuez toujours vos propres recherches avant d'investir.
-
Quelle est la précision des prédictions de Adma Biologics, Inc. ?
Notre IA atteint une corrélation de Spearman de -3% pour cette action, avec une précision moyenne supérieure à 67% sur plus de 4 000 actions analysées quotidiennement.
-
À quelle fréquence les prévisions sont-elles mises à jour ?
Les prévisions de Adma Biologics, Inc. sont mises à jour quotidiennement avec les dernières données de marché et les modèles d'IA.
Prêt à investir plus intelligemment ?
Rejoignez des milliers d'investisseurs utilisant des prédictions boursières propulsées par l'IA
Inscription gratuite✓ Compte gratuit · ✓ Plus de 4 000 actions · ✓ Mises à jour quotidiennes
Vous cherchez une analyse plus approfondie de Adma Biologics, Inc. ?
Voir l'analyse institutionnelle complète sur Intratio →Les prédictions IA sont basées sur des modèles historiques et ne doivent pas constituer la seule base pour les décisions d'investissement. Les performances passées ne garantissent pas les résultats futurs. Effectuez toujours vos propres recherches.